Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.37
+0.37 (3.70%)
At close: Mar 4, 2026, 4:00 PM EST
10.39
+0.02 (0.19%)
After-hours: Mar 4, 2026, 7:27 PM EST
Design Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Design Therapeutics stock have an average target of 15, with a low estimate of 13 and a high estimate of 18. The average target predicts an increase of 44.65% from the current stock price of 10.37.
Analyst Consensus: Buy
* Price targets were last updated on Jan 7, 2026.
Analyst Ratings
The average analyst rating for Design Therapeutics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Hold | 3 | 3 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 1 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $18 | Buy | Initiates | $18 | +73.58% | Jan 7, 2026 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $7 → $14 | Hold → Buy | Upgrades | $7 → $14 | +35.00% | Dec 3, 2025 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $6 → $13 | Hold → Buy | Upgrades | $6 → $13 | +25.36% | Nov 20, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -42.14% | Nov 6, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -61.43% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.33
from -0.88
EPS Next Year
-1.32
from -1.33
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.31 | -1.03 | ||||
| Avg | -1.33 | -1.32 | ||||
| Low | -1.37 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.